|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We found recurrent somatic missense mutations in 22 genes (including PIK3CA, ERBB2, and GNAS) and a widespread APOBEC cytidine deaminase mutagenesis pattern (TCW motif) in both adenocarcinoma (ACC) and squamous cell carcinomas (SCCs).
|
31624127 |
2019 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
GNAS mutations are present in colorectal traditional serrated adenomas, serrated tubulovillous adenomas and serrated adenocarcinomas with adverse prognostic features.
|
28164369 |
2017 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Comparisons between SCC and ADC identified differential rates for AR, ER, HER2 and GNAS with an increased presence in ADC (p-values all <0.05).
|
28536037 |
2017 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
GNAS mutations are not specific to neoplasms of the gastrointestinal tract, and clinicopathologic correlation is necessary in GNAS-mutated adenocarcinomas in the lung to determine the primary site of origin.
|
28776576 |
2017 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Molecular analyses revealed the gene mutations of GNAS in 6 (38%) of 16 DNGPs (4 [57%] adenomas, 1 [16%] NUMP, and 1 [33%] invasive adenocarcinoma) and APC in 4 of 15 (27%) DNGPs: no adenomas, 2 (33%) NUMPs, and 2 (67%) invasive adenocarcinomas.
|
27984236 |
2017 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We separately analysed GNAS in the adenocarcinoma and the IPMN component in the IPMN-associated adenocarcinomas.
|
25796395 |
2015 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Immunohistochemically, all the GNAS-mutated adenocarcinomas diffusely expressed MUC5AC, indicating gastric epithelial differentiation.
|
25867268 |
2015 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
All the GNAS-mutated LEGHs were negative for HPV DNA and p16 expression, whereas all the GNAS-mutated adenocarcinomas were positive for HPV DNA and/or p16 expression, implicating GNAS mutations in the development of LEGH and a minor subset of HPV-related cervical adenocarcinomas.
|
24145653 |
2014 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Mutations in GNAS were detected in 16 (39%) IPMNs and 2 (22%) IPMNs with adenocarcinoma.
|
24938521 |
2014 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The current study suggests that GNAS-mutated villous adenomas may not necessarily be direct precursors of associated adenocarcinomas.
|
24470207 |
2014 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The GNAS mutation is not observed in conventional ductal adenocarcinomas of the pancreas.
|
24498386 |
2014 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Activating GNAS mutations were found in 22 of the 35 pyloric gland adenomas (PGAs; 63%) but in none of the foveolar-type or intestinal-type adenomas or the adenocarcinomas.
|
23208952 |
2013 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Activating GNAS mutations were found in 20 of the 24 villous adenomas (83%) but were absent in all the other tumours, except for one tubulovillous adenoma (3%) and two adenocarcinomas (3%).
|
22374786 |
2012 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In eight cases, we could investigate invasive adenocarcinomas that developed in association with IPMNs containing GNAS mutations.
|
21775669 |
2011 |